Rituximab Biosimilar - Research Grade

Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry, 2023, 95, 44: 16116-16122.

Human

CD20

1.0 - 5.0 mg/ml

Human IgG1 Kappa

Humanized

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Rituximab.

Blue ice

CD20 is a B-cell surface phosphoprotein and one of the most extensively studied targets for B-cell depletion research. This research-grade anti-human CD20 recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of rituximab, built around the CD20 target for research use only. Manufactured to in vivo standards as an ultra-pure, low-endotoxin human IgG1-kappa, it is supplied in scalable milligram to gram quantities to support high-throughput and bulk laboratories. It functions as a consistent control and active reagent across preclinical applications including B-cell depletion studies, in vitro screening, in vivo models, ADCC assays, and antibody-drug conjugate development.

MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7

P11836

ICH3001-100ml ICH3002-100ml ICH3003-100ml

https://www.imgt.org/mAb-DB/